Call: +7 771 977 66 65, +7 705 421 2277
Sign in or Register
My basket

Astana Biomed Group, an authorized Abcam distributor in Central Asia

Abiomed homepage

  • Categories
    Signal Transduction
    Cancer
    Epigenetics and Nuclear Signaling
    Immunology
    Cell Biology
    Cardiovascular
    Neuroscience
    Tags & Cell Markers
    Kits/ Lysates/ Other
    Developmental Biology
    Microbiology
    Biochemicals
    Secondary antibodies
    Isotype/Loading Controls
    Antibody Arrays
  • About us
  • Partners
  • Contact
    Address

    Saryarka 32, 18, 010000, Astana city, Kazakhstan

    Telephone +7 771 977 66 65, +7 705 421 2277

    Email

    laboratory@ctlab.kz, orders@abiomed.kz

Back to category
Cancer Cell cycle Kinases/phosphatases Cdks

Momelotinib (CYT387), ATP-competitve JAK 1/2 selective inhibitor (ab141372)

Key features and details

  • Potent ATP-competitve JAK 1/2 selective inhibitor
  • CAS Number: 1056634-68-4
  • Purity: > 95%
  • Soluble in DMSO to 20mM.

  • Form / State: Solid
  • Source: Synthetic

You may also be interested in

Product image
Anti-CDK1 antibody (ab221197)
Product image
Anti-CDK1 (phospho Y15) antibody (ab47594)
CHIR99021, GSK3 inhibitor (ab120890)
Product image
Anti-CDK1 (phospho T161) antibody [EPR19546] - BSA and Azide free (ab251327)

Overview

  • Product name

    Momelotinib (CYT387), ATP-competitve JAK 1/2 selective inhibitor
  • Description

    Potent ATP-competitve JAK 1/2 selective inhibitor
  • Alternative names

    • CYT387
  • Biological description

    Potent ATP-competitive JAK 1/2 selective inhibitor (IC50 values are 11, 18 and 155 nM for JAK1, JAK2 and JAK3 respectively). Shows antiproliferative effects (IC50 = 4 μM, IL-3 stimulated Ba/F3 cells). Shows antitumor effects in vivo.
  • Purity

    > 95%
  • CAS Number

    1056634-68-4
  • Chemical structure

    Chemical Structure

Images

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Get resources and offers direct to your inbox Sign up
© 2021 Astana Biomed Group LLP. All rights reserved.